{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023728","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.452552+00:00","generated_at":"2026-05-16T19:11:26.489853+00:00","sec_items":["5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Qualigen shareholders approve all proposals; name change to AIxCrypto, Faraday Future becomes majority holder","bullets":["Stockholders approved private placement of 337,432 common shares and 39,943 Series B convertible preferred shares.","Faraday Future becomes majority owner with ~55% direct equity (incl. affiliates ~63%); will nominate majority of board.","Company rebrands to AIxCrypto Holdings, Inc., ticker changes to AIXC on Nov 20, 2025 from QLGN.","Company transitions from biotech to AI × Web3 platform, unveiling three-year roadmap at Nasdaq ceremony on Nov 20."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023728","json":"https://secwatch.observer/filing/0001493152-25-023728.json","markdown":"https://secwatch.observer/filing/0001493152-25-023728.md","text":"https://secwatch.observer/filing/0001493152-25-023728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315225023728/0001493152-25-023728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315225023728/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:11:26.489853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"678615cc351be2055e54a84de86a35113d72501e","claim":"AIxCrypto Holdings, Inc.: Changed corporate name from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc (effective 2025-11-14).","evidence_excerpt":"On November 14, 2025, Qualigen Therapeutics, Inc. (the “Company”) filed with the State of Delaware a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to change our corporate name from “Qualigen Therapeutics, Inc.” to “AIxCrypto Holdings, Inc.”","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315225023728/0001493152-25-023728-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-11-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}